Bristol-Myers Squibb (NYSE:BMY) announced a quarterly dividend on Thursday, December 19th, Stock Ratings Network reports. Stockholders of record on Friday, January 3rd will be paid a dividend of 0.36 per share on Monday, February 3rd. This represents a $1.44 annualized dividend and a dividend yield of 2.82%.
A number of research firms have recently commented on BMY. Analysts at TheStreet reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research note to investors on Monday, December 2nd. On the ratings front, analysts at Zacks reiterated a “neutral” rating on shares of Bristol-Myers Squibb in a research note to investors on Tuesday, November 19th. They now have a $54.00 price target on the stock. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $50.69.
Shares of Bristol-Myers Squibb (NYSE:BMY) opened at 52.59 on Thursday. Bristol-Myers Squibb has a 1-year low of $31.85 and a 1-year high of $53.68. The stock has a 50-day moving average of $51.84 and a 200-day moving average of $46.9. The company has a market cap of $86.592 billion and a price-to-earnings ratio of 30.67.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings data on Wednesday, October 23rd. The company reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.02. The company had revenue of $4.07 billion for the quarter, compared to the consensus estimate of $4.02 billion. During the same quarter in the previous year, the company posted $0.41 earnings per share. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. Analysts expect that Bristol-Myers Squibb will post $1.74 EPS for the current fiscal year.
Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.